Gary J. Kelloff
Impact in
- Pharmacology top 0.1%
- Inflammatory mediators and NSAID effects
- Cancer Research top 0.5%
- Carcinogens and Genotoxicity Assessment
Papers in
-
- Carcinogens and Genotoxicity Assessment 67
- Pharmacology 60
- Inflammatory mediators and NSAID effects 59
- Co-authors
- Vernon E. Steele (91 shared papers)Ronald A. Lubet (68 shared papers)Caroline C. Sigman (60 shared papers)Charles W. Boone (79 shared papers)Chinthalapally V. Rao (13 shared papers)James A. Crowell (43 shared papers)Karen Seibert (4 shared papers)Ernest T. Hawk (22 shared papers)
- Journals
- Journal of Cellular Biochemistry (43 papers)Carcinogenesis (15 papers)Clinical Cancer Research (13 papers)JNCI Journal of the National Cancer Institute (11 papers)European Journal of Cancer (6 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Gary J. Kelloff
311 papers receiving 19.9k citations
Gary J. Kelloff's Hit Papers
Peers
Comparison fields: 5 of 158
- Pharmacology 3.8k
- Cancer Research 2.6k
- Biochemistry 1.1k
- Oncology 2.8k
- Molecular Medicine 812
Countries citing papers authored by Gary J. Kelloff
This map shows the geographic impact of Gary J. Kelloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary J. Kelloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary J. Kelloff more than expected).
Fields of papers citing papers by Gary J. Kelloff
This network shows the impact of papers produced by Gary J. Kelloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary J. Kelloff. The network helps show where Gary J. Kelloff may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary J. Kelloff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 316 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis Hit paper breakdown → | 2000 | 2135 |
| 2 | Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Hit paper breakdown → | 2005 | 558 |
| 3 | Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. | 1999 | 531 |
| 4 | 2008 | 450 | |
| 5 | Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia Hit paper breakdown → | 2017 | 442 |
| 6 | The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. | 2000 | 435 |
| 7 | Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. | 2000 | 400 |
| 8 | 2000 | 394 | |
| 9 | 1999 | 365 | |
| 10 | Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. | 1990 | 358 |
| 11 | Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. | 2002 | 316 |
| 12 | 2012 | 287 | |
| 13 | 1999 | 283 | |
| 14 | Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. | 1996 | 275 |
| 15 | Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. | 1997 | 268 |
| 16 | 2000 | 240 | |
| 17 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. | 2000 | 235 |
| 18 | 2000 | 232 | |
| 19 | Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. | 1994 | 230 |
| 20 | 2006 | 228 |
About Gary J. Kelloff
Gary J. Kelloff is a scholar working on Cancer Research, Pharmacology, Oncology, Immunology and Molecular Biology, having authored 316 papers that have together received 21.5k indexed citations. Recurring topics across this work include Carcinogens and Genotoxicity Assessment (67 papers), Inflammatory mediators and NSAID effects (59 papers), T-cell and Retrovirus Studies (39 papers), Cancer and biochemical research (33 papers), Science, Research, and Medicine (22 papers), Bioactive Compounds and Antitumor Agents (16 papers), Estrogen and related hormone effects (16 papers) and Prostate Cancer Treatment and Research (15 papers). The work is most often cited by research in Pharmacology (3.8k citations), Cancer Research (2.6k citations), Biochemistry (1.1k citations), Oncology (2.8k citations) and Molecular Medicine (812 citations). Gary J. Kelloff has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Vernon E. Steele, Ronald A. Lubet, Caroline C. Sigman, Charles W. Boone, Chinthalapally V. Rao, James A. Crowell, Karen Seibert, Ernest T. Hawk, Ron Lubet and Bandaru S. Reddy. Their work appears in journals such as Journal of Cellular Biochemistry, Carcinogenesis, Clinical Cancer Research, JNCI Journal of the National Cancer Institute and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.